Viking Therapeutics (VKTX) to Post Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is expected to post its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Viking Therapeutics to post earnings of ($1.21) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.36). During the same quarter last year, the business posted ($0.41) EPS. On average, analysts expect Viking Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viking Therapeutics Stock Performance

VKTX stock opened at $34.79 on Monday. Viking Therapeutics has a 12-month low of $22.96 and a 12-month high of $43.15. The business’s 50-day moving average is $33.79 and its 200 day moving average is $32.93. The stock has a market cap of $4.04 billion, a price-to-earnings ratio of -8.40 and a beta of 0.66.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP increased its stake in shares of Viking Therapeutics by 58.7% in the 3rd quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company’s stock valued at $54,807,000 after buying an additional 771,704 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Viking Therapeutics by 41.8% during the third quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company’s stock valued at $55,000,000 after acquiring an additional 616,526 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Viking Therapeutics by 6,315.6% in the second quarter. Cubist Systematic Strategies LLC now owns 596,650 shares of the biotechnology company’s stock valued at $15,811,000 after acquiring an additional 587,350 shares during the last quarter. Duquesne Family Office LLC acquired a new stake in Viking Therapeutics in the second quarter worth about $14,556,000. Finally, Man Group plc raised its holdings in Viking Therapeutics by 2,628.8% during the 4th quarter. Man Group plc now owns 260,301 shares of the biotechnology company’s stock worth $9,157,000 after purchasing an additional 250,762 shares during the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on VKTX shares. BTIG Research reissued a “buy” rating and set a $125.00 price target on shares of Viking Therapeutics in a research report on Friday, May 1st. Truist Financial started coverage on shares of Viking Therapeutics in a report on Wednesday, May 27th. They issued a “buy” rating and a $83.00 target price on the stock. Lake Street Capital assumed coverage on shares of Viking Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $89.00 price target for the company. Morgan Stanley set a $95.00 price objective on Viking Therapeutics in a report on Thursday, April 30th. Finally, Zacks Research lowered Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $97.00.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.